Company news

PYC Therapeutics Limited news in 2025

PYC Therapeutics Limited's news releases, calls and decks from 2025, newest first.

View company

PKD Clinical Trial - Safety Outcomes in Part A

December 18, 2025

Sustained Vision Improvement in RP11 Patients

November 13, 2025

ADOA Program Initiation of Global Repeat Dose Study

October 20, 2025

PMS Program Data Supports Progression to Human Trials

October 12, 2025

ADOA Program Progressing to Multiple Dose Study

October 8, 2025

Board and Management Changes

September 21, 2025

Correction to Trading Halt Request

September 19, 2025

Change of Managing Director

September 16, 2025

ADOA Program - Presentation of Clinical Data at NOSA 2025

September 4, 2025

PKD Program - Presentation of Safety Data at ANZSN

August 28, 2025

Appendix 4E

August 28, 2025

Approval to Escalate Dosing in Kidney Disease Clinical Trial

August 7, 2025

Approval to Progress Kidney Disease Trial to Next Stage

July 6, 2025

Fourth Drug Program Progressing to Human Trials

June 26, 2025

FDA Alignment on Registrational Trial Design RP11 Program

June 22, 2025

SRC Approves Dose Escalation in ADOA Clinical Trial

June 10, 2025

Approval to Escalate Dosing in Kidney Disease Trial

May 25, 2025

Presentation of Clinical Proof of Concept in Lead Program

April 27, 2025

Completion of Entitlement Offer

April 16, 2025

First Subject Dosed in PKD Clinical Trial

April 9, 2025

Placement of Shortfall

April 9, 2025

Retail Entitlement Offer Booklet

February 24, 2025

Completion of Institutional Entitlement Offer

February 18, 2025

PYC Equity Raising Presentation

February 16, 2025

PYC Equity Raising to Raise up to $146 Million

February 16, 2025

Approval to Commence Human Trials in Kidney Program

February 9, 2025

ADOA Safety Review Committee Approves Dose Escalation

January 30, 2025

US FDA Grants Rare Pediatric Disease Designation to VP-001

January 19, 2025

Decks in 2025